What “Research Use Only” (RUO) Means in Greece and the EU

“Research Use Only” (RUO) is not a certification, not an approval, and not a quality grade. It is a statement of intended use made by the supplier, and in EU law it functions mainly as a negative statement: the material holds no marketing authorisation as a medicine, carries no CE marking as an in vitro diagnostic medical device, and is neither a food, a supplement, nor a cosmetic. The substance of the marking is what it does not say.

The confusion arises because the phrase looks like an official stamp. In fact, the only place in EU law where the term appears as a legally defined category concerns in vitro diagnostic products ^[1]. For a chemical reagent such as a synthetic peptide, the applicable framework is something else entirely: REACH and CLP, and — if the presentation allows it — medicines law ^[2][4][7]. What follows sets out what each of those means in practice for anyone receiving, checking and documenting material in a laboratory in Greece.

The short answer: a statement of intent, not a certification

The RUO marking describes what the supplier declares the material is intended to do. It does not describe what the material is, who analysed it, by which method, or with what result. No authority grants “RUO status” and no register records it. That does not make the marking empty: it delimits the frame within which the product may lawfully be supplied, and a supplier who steps outside that frame changes the legal category of the product ^[6].

• What it states: the intended use declared by the party placing the material on the market — laboratory research and nothing else.
• What it does not state: purity, identity, content, sterility or stability; those are evidenced solely by analytical data, batch by batch ^[9][10].
• What it does not replace: CLP classification and labelling and the safety data sheet, both mandatory regardless of any commercial wording ^[5][7].
• What it does not confer: any immunity. If the overall presentation implies therapeutic properties, the product can be classified as a medicinal product “by presentation” ^[2][3].

Where the term “research use only” actually exists in EU law

Regulation (EU) 2017/746 on in vitro diagnostic medical devices (the IVDR) expressly excludes from its scope products for general laboratory use and research use only products, unless the manufacturer specifically intends them for in vitro diagnostic examination ^[1]. The wording matters for two reasons. First, the test is the manufacturer's intention rather than the nature of the molecule: the same reagent can sit inside or outside the scope depending on what that manufacturer declares. Second, the exclusion is conditional rather than permanent — it collapses the moment the manufacturer attaches a diagnostic purpose, at which point the product is suddenly inside the IVDR without a CE mark.

This Regulation shall not apply to products for general laboratory use or research use only products, unless such products, in view of their characteristics, are specifically intended by their manufacturer to be used for in vitro diagnostic examination.

Regulation (EU) 2017/746, Article 1(3)(a)

No other EU instrument defines the term. The U.S. FDA, however, articulated the underlying principle more explicitly than any European text: in a 2013 guidance it states that RUO labelling must be consistent with the manufacturer's actual intended use, and that the agency weighs the totality of the circumstances — advertising material, technical support, statements by the sales network — and not merely the phrase printed on the packaging ^[6]. The document is not binding in the EU, but it describes how any market surveillance authority reasons: the label is a claim, conduct is the evidence.

Why the label alone does not settle the legal category

Directive 2001/83/EC defines a medicinal product through two alternative limbs: any substance presented as having properties for treating or preventing disease (“by presentation”), and any substance that may be used or administered with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action (“by function”) ^[2]. The first limb does not depend on pharmacology at all; it depends entirely on what the seller says.

The directive also contains a doubt clause: where a product may fall both within the definition of a medicinal product and within the scope of other Union legislation, medicines law prevails ^[2]. The Court of Justice has narrowed the second limb: in Case C-140/07 (Hecht-Pharma), judgment of 15 January 2009, it held that a product is a medicinal product by function only where it is capable of appreciably restoring, correcting or modifying physiological functions, and that classification is made case by case, taking account of composition, pharmacological properties, manner of use, extent of distribution and attendant risks ^[3]. The first limb, by contrast, remains broad and requires no pharmacological proof whatsoever.

In practice, “presentation” is not only the label. It is the packaging, the accompanying material, the catalogue description, the answers given to customer questions, even the context in which a product is displayed. An RUO marking printed on a container does not neutralise text promising physiological effects in people; the contradiction simply makes the marking unpersuasive to an authority. Substances such as semaglutide hold marketing authorisation as medicines in the EU through the centralised procedure, while many other peptides hold no authorisation anywhere. Both categories fall outside the lawful scope of a research supply the moment the presentation shifts toward people.

The regime that actually applies: REACH, CLP and the safety data sheet

For a synthetic peptide moving as a chemical reagent, the real regulatory framework is REACH. Article 3(23) defines “scientific research and development” as any scientific experimentation, analysis or chemical research carried out under controlled conditions in a volume of less than one tonne per year ^[4]. That one-tonne threshold is also the registration threshold, so research quantities in practice already sit below the registration duty. This explains why there is no “REACH registration number” for a research peptide, and why its absence is not an omission — but equally why its absence is, by itself, no indication of quality.

Regulation (EC) No 1272/2008 (CLP) requires substances to be classified, labelled and packaged according to harmonised hazard criteria: substance identifiers, pictograms, a signal word, hazard statements and precautionary statements ^[7]. The phrase “research use only” is additional commercial text and substitutes for none of those elements. Where packaging carries the RUO wording but no hazard information, the gap is in the CLP labelling, and it is a reasonable ground to hold the receipt pending clarification from the supplier.

The document with the greatest practical value at receipt is the safety data sheet. Article 31 and Annex II of REACH set out its content, and since 1 January 2023 every safety data sheet circulating in the EU must follow the format introduced by Commission Regulation (EU) 2020/878: sixteen mandatory sections, with added requirements covering nanoforms, endocrine disrupting properties, specific concentration limits and the unique formula identifier ^[5]. A sheet in an older format, or one that reproduces generic text without a specific substance identification, is itself information about the supplier.

Who supervises what in Greece: EOF, ESYD, ELOT

In Greece the competences are distributed, and they do not overlap in the way that is commonly assumed. None of the bodies most often invoked as a “guarantee” approves research reagents, and citing them in commercial material is a category error before it is anything else.

The distinction has an immediate consequence for certificates of analysis. Accreditation attaches to the laboratory and to its specific scope of methods, not to the material examined; Regulation (EC) No 765/2008 obliges each Member State to designate one and only one national accreditation body, a role performed in Greece by ESYD ^[8]. A certificate of analysis is therefore worth exactly as much as its issuer, which is the argument for reading the certificate field by field: the laboratory's name, the accreditation certificate number, and confirmation that the particular method sits inside the published scope. ELOT EN ISO/IEC 17025 requires documented personnel competence, metrological traceability, the use of reference materials and participation in proficiency testing — requirements that a logo pasted into a PDF does not satisfy ^[11].

What the RUO marking does not guarantee about quality

The analytical literature is clear that provenance does not settle identity. In a quality control study published in Analytical Biochemistry in 2008, researchers examined obestatin samples from five different manufacturers by liquid chromatography with photodiode array detection, fluorescence detection and mass spectrometry. One of the products was in reality an entirely different peptide, while two thirds of the remainder showed purity below 95% or individual impurities above 1% — levels the authors judged insufficient for in vitro and in vivo experiments, and which they linked to the contradictory findings then circulating in the literature about that same peptide ^[9].

The second finding concerns the difference between “purity” and “content”, the most common misreading of a certificate of analysis. In work published in the Journal of Pharmaceutical and Biomedical Analysis in 2019, nuclear magnetic resonance spectroscopy revealed undeclared mannitol in custom synthetic peptides at 20–43% by weight, undetected by the chromatographic purity test supplied with the products ^[10]. The reason is structural: what an RP-HPLC purity figure actually measures is peak area under UV detection, expressed as a percentage, and an excipient that does not absorb at the detection wavelength simply never registers. A purity figure says nothing about how much of the contents by mass is peptide.

It is worth stating plainly how limited this evidence is, because the opposite practice is the norm in this field. Both papers are small analytical studies of specific samples rather than systematic market surveys, and neither examines the current European supply of research peptides ^[9][10]. There is no published, independent review of quality across that market in the EU, and the testing that has been published on commercially sold vials does not add up to one. Anyone quoting adulteration rates with confidence is guessing. The defensible conclusion is more modest and more useful: the identity and composition of a sample are established only by measurement, batch by batch, and never by the phrase printed on the label.

What the documentation file should show

If the RUO marking certifies nothing, the weight shifts entirely onto the documents that accompany it. Measured against the obligations set out above, the minimum file for a batch entering a laboratory in Greece is reasonably specific ^[5][7][11].

• CLP labelling with substance identifiers, pictograms, a signal word and hazard statements — not merely the phrase “for research use only” ^[7].
• A sixteen-section safety data sheet in the format of Commission Regulation (EU) 2020/878, in a language accepted in the Member State of delivery ^[5].
• A certificate of analysis whose batch number matches the labelling on the container, with an issue date and a named issuing laboratory.
• An explicit statement of method: RP-HPLC with a declared detection wavelength for purity, and mass spectrometry with observed against theoretical monoisotopic mass for identity.
• A statement of what the purity figure actually measures — percentage of peak area, not peptide content — and, where available, a separate content determination ^[10].
• The accreditation scope of the laboratory that issued the certificate, verifiable in the ESYD register or that of an equivalent body signatory to the EA MLA ^[8].
• An internal receipt record: date, condition of packaging, transport conditions and storage location, so the documentation chain begins on day one.

“Research use only” is, in the end, a boundary rather than a permission. It defines the frame within which material is lawfully supplied and outside which its legal category changes, with consequences that fall on supplier and recipient alike ^[1][2][6]. The quality, identity and hazard characterisation of the material never follow from that phrase; they follow from CLP labelling, the safety data sheet, the analytical data for the specific batch, and the demonstrated competence of the laboratory that produced them.